Dual Trop-2 and Nectin-4 ADC Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for relapsed or refractory locally advanced or metastatic urothelial carcinoma, such as ADCs, face limitations due to tumor heterogeneity, emergence of resistant clones, and tolerability issues, leading to suboptimal clinical outcomes.
Innovation Solution
A combination therapy approach using a therapeutically effective amount of a Trop-2 antibody-drug conjugate (Trop-2 ADC) and a Nectin-4 antibody-drug conjugate (Nectin-4 ADC) is administered to patients, potentially alongside an anti-PD-1 antibody or anti-PD-L1 antibody, to enhance efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If ADC monotherapy is used to treat relapsed or refractory urothelial carcinoma, then treatment simplicity is maintained, but clinical efficacy is limited due to tumor heterogeneity and resistant clones
Solution Approach 1:
The patent combines two different ADCs (Trop-2 ADC and Nectin-4 ADC) into a single treatment regimen to address tumor heterogeneity and prevent resistant clone emergence. This merging of therapies targets multiple antigens simultaneously, improving clinical efficacy while managing the complexity through a coordinated combination approach.
2Productivity
If combination therapy with multiple ADCs is used to overcome tumor heterogeneity, then clinical efficacy is improved, but tolerability and safety profile worsen due to cumulative toxicities
Solution Approach 1:
The patent modifies dosing parameters of the combination therapy, including dose reduction of one or both ADCs, extended dosing intervals, or sequential administration schedules. These parameter changes maintain the synergistic anti-tumor effect while reducing cumulative toxicities to acceptable levels, thereby improving the therapeutic index.
3Productivity
If higher doses of ADC are administered to improve response rate, then antitumor efficacy increases, but treatment-related adverse events increase
Solution Approach 1:
The patent combines two ADCs with different mechanisms of action and toxicity profiles (Trop-2 ADC targeting neuronal tissues and Nectin-4 ADC targeting renal tissues) to achieve synergistic anti-tumor effects at lower individual doses. This combination approach improves overall response rate while distributing and managing toxicities across different organ systems, reducing serious treatment-related adverse events.
Data Source
AI summary
This disclosure provides methods for treating cancer in a patient, the methods including administering a combination therapy comprising dual antibody drug conjugates. In some embodiments the combination therapy comprises (i) a therapeutically effective amount of a Trop-2 antibody-drug conjugate (Trop-2 ADC), (ii) a therapeutically effective amount of a Nectin-4 antibody-drug conjugate (Nectin-4 ADC), and, optionally, (iii) a therapeutically effective amount of an anti-PD(L)-1 antibody. In some embodiments, the cancer is urothelial carcinoma.